• Login
    View Item 
    •   Mak IR Home
    • College of Health Sciences (CHS)
    • School of Health Sciences (Health-Sciences)
    • School of Health Sciences (Health-Sciences) Collections
    • View Item
    •   Mak IR Home
    • College of Health Sciences (CHS)
    • School of Health Sciences (Health-Sciences)
    • School of Health Sciences (Health-Sciences) Collections
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults

    Thumbnail
    View/Open
    Article (146.7Kb)
    Date
    2008-12-19
    Author
    Byakika-Tusiime, Jayne
    Chinn, Leslie W.
    Oyugi, Jessica H.
    Obua, Celestino
    Bangsberg, David R.
    Kroetz, Deanna L.
    Metadata
    Show full item record
    Abstract
    Background: Generic antiretroviral therapy is the mainstay of HIV treatment in resource-limited settings, yet there is little evidence confirming the bioequivalence of generic and brand name formulations. We compared the steady-state pharmacokinetics of lamivudine, stavudine and nevirapine in HIV-infected subjects who were receiving a generic formulation (TriomuneH) or the corresponding brand formulations (EpivirH, ZeritH, and ViramuneH). Methodology/Principal Findings: An open-label, randomized, crossover study was carried out in 18 HIV-infected Ugandan subjects stabilized on Triomune-40. Subjects received lamivudine (150 mg), stavudine (40 mg), and nevirapine (200 mg) in either the generic or brand formulation twice a day for 30 days, before switching to the other formulation. At the end of each treatment period, blood samples were collected over 12 h for pharmacokinetic analysis. The main outcome measures were the mean AUC0–12h and Cmax. Bioequivalence was defined as a geometric mean ratio between the generic and brand name within the 90% confidence interval of 0.8–1.25. The geometric mean ratios and the 90% confidence intervals were: stavudine Cmax, 1.3 (0.99–1.71) and AUC0–12h, 1.1 (0.87–1.38); lamivudine Cmax, 0.8 (0.63–0.98) and AUC0–12h, 0.8 (0.65–0.99); and nevirapine Cmax, 1.1 (0.95–1.23) and AUC0–12h, 1.1 (0.95–1.31). The generic formulation was not statistically bioequivalent to the brand formulations during steady state, although exposures were comparable. A mixed random effects model identified about 50% intersubject variability in the pharmacokinetic parameters. Conclusions/Significant Findings: These findings provide support for the use of Triomune in resource-limited settings, although identification of the sources of intersubject variability in these populations is critical.
    URI
    http://hdl.handle.net/10570/1061
    Collections
    • School of Health Sciences (Health-Sciences) Collections

    DSpace 5.8 copyright © Makerere University 
    Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of Mak IRCommunities & CollectionsTitlesAuthorsBy AdvisorBy Issue DateSubjectsBy TypeThis CollectionTitlesAuthorsBy AdvisorBy Issue DateSubjectsBy Type

    My Account

    LoginRegister

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    DSpace 5.8 copyright © Makerere University 
    Contact Us | Send Feedback
    Theme by 
    Atmire NV